Pancreatic Cancer Diagnostic Market Expected to Reach $3.2 Billion by 2035

According to a new report published by Allied Market Research, titled, “Pancreatic Cancer Diagnostic Market," The pancreatic cancer diagnostic market size was valued at $1.6 billion in 2023, and is estimated to reach $3.2 billion by 2035, growing at a CAGR of 5.9% from 2024 to 2035. Pancreatic cancer diagnosis refers to the medical process used to detect the presence of cancer in the pancreas, an organ responsible for producing digestive enzymes and hormones like insulin. The diagnosis typically involves a combination of imaging techniques, such as CT scans, MRIs, and ultrasounds, to identify abnormal growths or tumors. In addition, blood tests, including markers such as CA 19-9, help in assessing the likelihood of cancer. A biopsy, where a sample of tissue is removed for examination, is often necessary to confirm the diagnosis. Early detection is challenging due to the pancreas's deep location and the vague symptoms associated with the disease, making regular screenings crucial for individuals at high risk. 

The pancreatic cancer diagnostic market growth is driven by rise in incidence of pancreatic cancer. As the global population ages, the number of individuals at higher risk for pancreatic cancer continues to grow. In addition, pancreatic cancer diagnostic market trends includes lifestyle factors such as smoking, poor diet, obesity, and a sedentary lifestyle lead to increase in prevalence of pancreatic cancer, especially in developed countries.  

However, high cost of advanced diagnostic technologies, such as molecular tests, liquid biopsy, and specialized imaging techniques, which can limit accessibility, especially in low-income or resource-constrained regions, restrains the market growth. On the other hand, rise in technological advancements in diagnostics tools provides a lucrative pancreatic cancer diagnostic market opportunity. Rise in awareness and education about pancreatic cancer also presents an pancreatic cancer diagnostic market growth, as patients and healthcare professionals are increasingly prioritizing early diagnosis.

The pancreatic cancer diagnostic market size is segmented into product, test type, cancer type, end user, and region. By product, the market is segregated into instruments and consumables. The consumables segment dominated the market share in 2023, owing to high demand for diagnostic tests and reagents used in pancreatic cancer detection. Consumables, such as biomarkers, test kits, and assay reagents, are essential for the accurate and consistent performance of diagnostic devices. Their recurring need for diagnostic procedures further contributed to their market dominance.  

However, the instrument segment is expected to register the highest CAGR during the forecast period due to increase in the adoption of advanced diagnostic technologies, such as imaging systems, molecular diagnostic instruments, and liquid biopsy devices. These instruments offer higher accuracy, efficiency, and early detection capabilities.  

On the basis of test type, the market is classified into imaging test, blood test, and biopsy. The imaging test segment accounted for the largest pancreatic cancer diagnostic market share in 2023, owing to widespread use of advanced imaging techniques such as CT scans, MRIs, and PET scans for detecting pancreatic cancer. These methods are highly effective in providing detailed visual insights into the pancreas, aiding in early detection, staging, and treatment planning. The ability of imaging tests to detect tumors at various stages and their non-invasive nature further contribute to their dominant position in the market.

On the basis of cancer type, the market is classified into exocrine and endocrine. The exocrine segment is further categorized into adenocarcinoma, adenosquamous carcinoma, and others. The exocrine segment accounted for the largest pancreatic cancer diagnostic market share in 2023 and is expected to register the highest CAGR during the forecast period, owing to the higher prevalence of exocrine pancreatic cancer, which involves the majority of pancreatic cancer cases. Exocrine pancreatic cancer is typically diagnosed through imaging tests and biomarker assays, making it a major focus in diagnostic procedures.  

On the basis of end user, the market is categorized into hospitals, diagnostic centers, and others. The hospitals segment accounted for the largest share in 2023, as hospitals play a central role in the diagnosis and treatment of pancreatic cancer. Hospitals are equipped with advanced diagnostic technologies, such as imaging systems and laboratory facilities, which enable accurate and timely detection of pancreatic cancer.  

However, the diagnostic centers segment is expected to register the highest CAGR during the pancreatic cancer diagnostic market forecast period. This is attributed to increase in demand for specialized diagnostic services and rise in the number of diagnostic centers equipped with advanced imaging and molecular diagnostic technologies.  

Region-wise, North America dominated the pancreatic cancer diagnostic industry in 2023, owing to advanced healthcare infrastructure, high adoption of cutting-edge diagnostic technologies, and significant investments in cancer research. The region also benefits from a large number of diagnostic centers and hospitals equipped with state-of-the-art tools. However, Asia-Pacific is anticipated to witness notable growth during the forecast period owing to rapid improvements in healthcare infrastructure, increased investments in advanced diagnostic technologies, and rise in awareness of early cancer detection. Rise in prevalence of pancreatic cancer, coupled with a large aging population, is driving demand for better diagnostic solutions.

Key findings of the study  

• On the basis of product, the consumables segment was largest contributor to the pancreatic cancer diagnostic industry in 2023. However, the instrument segment is anticipated to grow at the highest CAGR during the forecast period. 
• On the basis of test type, the imaging test segment was largest contributor to the market in 2023. On the basis of cancer type, the exocrine segment was largest contributor to the market in 2023.  
• On the basis of end user, the hospitals segment was largest contributor to the market in 2023.
• Region-wise, North America generated the largest revenue in 2023. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.